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The amyloid precursor protein (APP) is implied both in cell
growth and differentiation and in neurodegenerative pro-
cesses in Alzheimer disease. Regulated proteolysis of APP
generates biologically active fragments such as the neuropro-
tective secreted ectodomain sAPP and the neurotoxic
-amyloid peptide. Furthermore, it has been suggested that
the intact transmembrane APP plays a signaling role, which
might be important for both normal synaptic plasticity and
neuronal dysfunction in dementia. To understand APP sig-
naling, we tracked single molecules of APP using quantum
dots and quantitated APP homodimerization using fluores-
cence lifetime imaging microscopy for the detection of Fo¨r-
ster resonance energy transfer in living neuroblastoma cells.
Using selective labeling with synthetic fluorophores, we show
that the dimerization of APP is considerably higher at the
plasma membrane than in intracellular membranes. Heparan
sulfate significantly contributes to the almost complete
dimerization of APP at the plasma membrane. Importantly,
this technique for the first time structurally defines the initi-
ation of APP signaling by binding of a relevant physiological
extracellular ligand; our results indicate APP as receptor for
neuroprotective sAPP, as sAPP binding disrupts APP
dimers, and this disruption of APP dimers by sAPP is nec-
essary for the protection of neuroblastoma cells against star-
vation-induced cell death. Only cells expressing reversibly
dimerized wild-type, but not covalently dimerized mutant
APP are protected by sAPP. These findings suggest a poten-
tially beneficial effect of increasing sAPP production or dis-
rupting APP dimers for neuronal survival.
The amyloid precursor protein (APP)4 is known both for its
important role in the development and plasticity of the nervous
system (1–6) and for its involvement inAlzheimer disease (AD)
(7, 8). Despite intensive research efforts, the initial events that
lead to the prevalent sporadic, i.e. non-familial, forms of AD are
still unclear. Furthermore, although a higher gene dose of APP
(9) or the presence of pathological APP mutations is sufficient
to induce familial AD (for review, see Ref. 10), the exact patho-
logical mechanism that is triggered byAPP is still under debate.
Some fragments of APP, such as the -amyloid peptide
(A), are thought to contribute to synaptic dysfunction and
neurotoxicity (11, 12). On the other hand, the -secretase-
derived extracellular fragment of APP (sAPP), which is
present at lower levels in AD patients than in controls (13),
has been shown to be beneficial for memory function, to
possess neuroprotective properties, and to counteract the
effects of A (14–18).
Signaling by transmembrane APPmay directly contribute to
neurodegeneration in AD (19–24); however, the signal trans-
duction pathway for transmembrane APP remains unknown,
although several potential regulatory proteins, glycosaminogly-
cans, andmetal ions are known to bindwith high affinity toAPP
and sAPP (25, 26). The most common form of signal trans-
duction for single-pass transmembrane proteins is the ligand-
induced perturbation of a monomer/dimer equilibrium.
Indeed, the dimerization of transmembrane APP has been
implied several times in the past. Several studies have investi-
gated the effects of presumed dimer-breaking perturbations on
biological read-outs, such as the production of A (27, 28), but
without directly measuring the APP aggregation state, or have
investigated the aggregation state of APP subdomains, often
reconstituted in cell-free systems (27–32). Dimerization inter-
faces in both the extracellular and the transmembrane domain
have been suggested.
In the studies investigating the aggregation state of full-
length APP, most of the employed methods, such as chemical
cross-linking and co-immunoprecipitation, do not lend them-
selves readily to a rigorous quantitative analysis of the abun-
dance of potentially instable dimers (31, 33), whereas in other
cases the use of chimerasmay have influenced the dimerization
potential or precluded the search for a natural stimulus (23, 34).
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The only previously reported direct observation of APP dimer-
ization by Fo¨rster resonance energy transfer (FRET) micros-
copy uses an assay in which the FRET efficiency varies with the
level of overexpression (35). Therefore, a concentration-
dependent FRET component due to nonspecific stochastic
encounters cannot be excluded in this study.
Most importantly, as none of the published procedures per-
mitted the selective detection of APP dimers on the surface of
live cells, where they would encounter ligands, they could not
differentiate between subpopulations of APP. This may be one
reason why no natural ligand of APP has ever been shown to
signal via modulation of its monomer/dimer equilibrium.
Another elusive goal is the identity of the receptor for neu-
roprotective sAPP (36–39). The ligand-dependent dimeriza-
tion of sAPP in solution (40) and its origination from trans-
membrane APP suggest that APP might serve as receptor for
sAPP, but this binding has never been experimentally shown.
EXPERIMENTAL PROCEDURES
Plasmids—pcDNA3-mGFP was obtained by cloning mono-
merized enhanced GFP (L222K mutation (41) produced from
pEGFP-N1 (Clontech,Mountain View, CA) using QuikChange
(Stratagene, La Jolla, CA)), flanked by NotI and XhoI primers,
into the NotI and SalI sites of pcDNA3 (all restriction enzymes
were from New England Biolabs, Ipswich, MA). APP-mGFP
was derived by inserting APP695 into the EcoRV andNotI sites
of pcDNA3-mGFP; anAAAG linker connects theC terminus of
APP to the N terminus of mGFP. For substitution of the fluoro-
phore, mGFP was excised using NotI and ApaI; mCherry ((42),
a kind gift of S. Eimer, European Neuroscience Institute Go¨t-
tingen) or REACh2 (43) was amplified using NotI and ApaI
primers and inserted in its place. The K624C mutants were
produced by using QuikChange on the XhoI-NotI fragment of
APP-mGFP and inserting the mutant fragment back into a
wild-type vector (K624C-APP-mGFP and K624C-APP-
mCherry). APP-ACP-mGFP and K624C-APP-ACP-mGFP
were obtained by silent mutation of APP695 codons 294–295
in the EcoRV-XhoI fragment of APP-mGFP to introduce an
NheI site (GCCAGT to GCTAGC) and insertion of acyl carrier
protein (ACP; Covalys Biosciences AG, Witterswil, Switzer-
land), and amplified using NheI-encoding forward and back-
ward primers into the corresponding site thus created. ACP
was, therefore, inserted in a similar position as the Kunitz pro-
tease inhibitor domain, which occurs in non-neuronal isoforms
of APP. The EcoRV-XhoI fragment was then inserted into
either wild-type APP-mGFP or K624C-APP-mGFP. To elimi-
nate mGFP from these vectors, wild-type APP-ACP and
K624C-APP-ACP were obtained by digestion with NotI and
PspOMI followed by religation. The entire open reading frames
of all constructs were confirmed by sequencing (SeqLab, Go¨t-
tingen, Germany).
Cell Culture—B103 neuroblastoma cells were a kind gift
fromDr. David Schubert (Salk Institute). APP or APP-like pro-
tein 2 cannot be detected in these cells (44). Cells were plated at
105 cells/well in Dulbecco’s modified Eagle’s medium  10%
fetal calf serum on poly-L-ornithine-coated glass coverslips in
24-well plates (Corning Life Sciences, Lowell, MA) and trans-
fected using 0.2–0.8g of plasmid DNA per well andmagnetic
nanoparticle MaTra beads on a 24-magnet plate (beads and
magnet from IBA GmbH, Go¨ttingen, Germany). The medium
was changed 1–2 h after transfection, and expression was
allowed to proceed for a further 16–24 h. MaTra transfection
was superior to several liposomal transfection methods in rep-
licating the expression pattern of endogenous APP and in
maintaining cell morphology (data not shown). For mGFP
imaging, coverslips were washed by a short immersion in phos-
phate-buffered saline andmounted on a drop of imaging buffer
(135 mM NaCl, 10 mM KCl, 0.4 mMMgCl2, 2 mM CaCl2, 10 mM
HEPES, 0.1% bovine serum albumin, 20% glucose) using a
homemade silicone rubber gasket on a glass slide. For ACP
imaging, coverslips were incubated for 20 h at 16 °C in a humid-
ified atmosphere in imaging buffer containing 10 mM MgCl2, 1
M wild-type ACP synthase (purified according to instructions
from Covalys Biosciences AG, Witterswil, Switzerland), and
CoA dyes (Covalys) at a concentration of 1 M CoA-488 and 3
M CoA-547, where indicated. They were then thoroughly
washed twice by immersion in phosphate-buffered saline and
draining off the excess liquid andmounted in imaging buffer as
formGFP imaging.Where indicated, 1M recombinant human
sAPP695 or sAPPa770 (45) was added to the imaging buffer
after removal of the dyes. The measurements started 10 h
after the addition of sAPP to the cells. To remove cell surface
heparin, cells were incubated for 2 hwith 2 units/ml heparinase
I (Sigma-Aldrich) in complete medium before labeling; hepari-
nase was also present during labeling with CoA dyes.
For quantum dot experiments, 1 M CoA coupled to biotin
was used. After washing, the cells were incubated with the indi-
cated concentration of streptavidin-coated 585-nm and/or
655-nm emitting quantum dots (Invitrogen) (46).
In survival experiments, B103 cells were transfected with 0.2
g of a yellow fluorescent protein construct (TN-XXL, a kind
gift ofOliverGriesbeck,MPI for Biochemistry,Munich) and 0.2
g of either pcDNA3, pcDNA3-APP, or pcDNA3-K624C-APP
per well using MaTra. 6 h after transfection wells were washed
once with phosphate-buffered saline and filled either with
imaging buffer or with imaging buffer containing 16 nM
sAPP770. In some experiments 24 h after transfection another
16 nM were added to the same wells.
Microscopy—Fluorescence lifetime imaging measurements
were performed on a frequency domain setup (47) using an
argon laser (Innova 304C, Coherent, Dieburg, Germany) at 488
nm (mGFP) or 496 nm (CoA-488). The presence of other flu-
orophores was confirmed using mercury lamp excitation. All
filter cubes were from AHF (Tu¨bingen, Germany) with the fol-
lowing components: mGFP dichroic LP495, emission BP 515/
30; CoA-488 dichroic LP515, emission BP 535/30; CoA-547
excitation BP 545/30, dichroic LP565, emission BP615/75;
mCherry excitation BP530–585, dichroic LP600, emission
BP615. mGFP imaging was performed at 22 °C; ACP imaging
was performed at 16 °C to slow down internalization of the
labeled APP, necessary to image APP at the cell surface. Eight-
phase step images were acquired in random order. Confocal
microscopy was performed at room temperature on a Zeiss
LSM-510 Meta instrument using laser excitation at 488 or 633
nm and a 63 water immersion objective or on a programma-
ble array microscope fitted on an Olympus IX71 microscope
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using laser excitation at 488 nm and a 150 oil immersion
objective (48). Quantum dot tracking was performed using the
View5D plugin (Rainer Heintzmann, King’s College, London)
for ImageJ (National Institutes of Health), and diffusion coeffi-
cients were calculated from the exported coordinates as
described before (49).
Statistical Analysis—InmGFP images, the optimal threshold
was set automatically (opthrmodule forMatLab by F. T.Marti).
All further operations were performed with custom-written
routines (AlessandroEsposito andM.Gralle) inMatLab (Math-
Works, Natick, MT). ACP images were manually threshold to
the smallest mask that includes the entire cell body; a contour
mask was then applied that extended 10 pixels inward from the
boundaries of the threshold mask to isolate the plasma mem-
brane. The lifetime and total intensity values of each pixel in the
threshold mask (mGFP) or contour mask (ACP) were stored
together with an estimate of the background fluorescence
(median intensity of the pixels outside the thresholdmask). For
each pixel, the signal to noise ratio (SNR) was calculated as the
quotient of its total intensity over the background fluorescence
in the image. SNRs and apparent lifetimes for all pixels in the
appropriatemasks of all cells were joined for each experimental
condition and imported into IgorPro (WaveMetrics, Lake
Oswego, Oregon) for fitting.
ACP Regression Analysis—As the ACP labeling creates a
small but non-negligible nonspecific background fluorescence,
the lifetime of specifically labeled APP () and the nonspecific
background (b) for each condition were estimated by fitting
SNR and apparent lifetimes (app) in all pixels to
app b /SNR  (Eq. 1)
The parameter b was linked in a global fit across all experi-
mental conditions, returning a value of 3.55 ns. Histograms
show the corrected lifetimes, obtained by inversion of (1),
  app  SNR b/SNR 1 (Eq. 2)
As the mean of the distribution of corrected lifetimes is
independent of SNR but its width increases with lower SNR
(data not shown), only pixels with a signal-to-noise4 were
included in the histograms for display purposes. These his-
tograms were fitted to a Gaussian distribution using the
IgorPro inbuilt function.
RESULTS
We investigated the oligomerization state of APP in living
B103 neuroblastoma cells by measuring FRET (50) using fluo-
rescence lifetime imaging microscopy (51). This technique is
able to detect the association of proteins in their natural, unper-
turbed environment. The association of the donor with the
acceptor fluorophore is reflected in a characteristic reduction
in the excited state lifetime of the donor. In our initial experi-
ments, we used APP-mGFP as donor and APP-mCherry as
acceptor. APP-mGFP displays a largely vesicular staining local-
ized predominantly to perinuclear membranes, most likely the
secretory compartments (endoplasmic reticulum and Golgi
apparatus), which is identical to the distribution of APP in cells
that express it endogenously (52) (Fig. 1, A, B, and E). APP-
mCherry localizes to the same cell compartments (Fig. 1F). The
excited state lifetime of the mGFP fluorophore in APP-mGFP
in the absence of acceptor is homogeneous, with a mean life-
time of 2.37  0.01 ns (Fig. 1D). In the presence of APP-
mCherry, however, the lifetime of APP-mGFP decreases to a
mean value of 2.17  0.01 ns, corresponding to a FRET effi-
ciency of 8.3  0.6% (Fig. 1G). This indicates that a portion of
the co-localizing APP-mGFP and APP-mCherry molecules is
closer together than 10 nm, i.e. physically interacts (50). Co-
expression of APP-mGFP with APP-REACh2 (43) resulted in
similar results (data not shown). It is important to note that
much less FRETwas observed in formaldehyde-fixed cells. This
suggests that the association of APPmolecules is labile and can
easily be disturbed and disrupted by changes in the membrane
environment. This apparent instability could explain why only
very low amounts of dimerized APP are observed in cell lysates
(31).
To allow an interpretation of FRET efficiency in terms of
degree of association, we employed a standard that is quantita-
tively dimerized. The K624Cmutant of APP has been shown to
form disulfide-bridged dimers and to dimerize quantitatively
(31). Furthermore, as the B103 cell line does not contain detect-
able levels of endogenous APP or related APP-like proteins
(44), it can be assumed that APP-mCherry only competes with
other APP-mGFP molecules for binding to APP-mGFP.
Mutant APP-mGFP displayed amean lifetime of 2.06 0.02 ns
in the presence ofmutant acceptor APP-mCherry, correspond-
ing to a FRET efficiency of 13.1  1.0% (Fig. 1H). The FRET
efficiency of wild-type APP corresponds to65% of the quan-
titatively dimerized mutant. Because the fluorophores are
expected to undergo little orientation restriction at the ends of
the unstructured cytoplasmic domain of APP (53), it is reason-
able to assume that the presence of the mutation in the trans-
membrane domain of APP does not noticeably affect the FRET
coupling of the fluorophores. Moreover, as the proportion of
APP-mGFP to APP-mCherry is the same for both mutant and
wild-type forms, the degree of association is proportional to the
FRET efficiency. It can, therefore, be concluded that wild-type
cellular APP is 35% monomeric (Figs. 1H and 3), with the rest
being dimers, as suggested fromx-ray diffraction and scattering
studies of APP fragments (32, 40) or higher oligomers.
Although intracellular APPmay already be cleaved to biolog-
ically active fragments (54, 55) and may serve additional roles
(56), only plasmalemmal APP can act as receptor for extracel-
lular molecules or metal ions. The strong signal of intracellular
APP-mGFP prevented us from detecting an effect for several
extracellular ligands on the aggregation state of APP (Fig. 3 and
data not shown). The quantity of cell surface APP is tightly
regulated by its very rapid turnover (57) and varies considerably
between different cell types and in different activation states,
independently of the total quantity of cellular APP (58, 59). The
reason for this tight regulation might be that the activation of
cell surface APP is toxic under certain circumstances (19, 20,
22–24). It is, therefore, essential to address the aggregation
state of cell surface APP separate from total cellular APP.
We did not succeed in isolating the very faint fluorescence
lifetime imaging microscopy signal of plasma membrane APP-
mGFP. The use of antibodies on living cells may have a cluster-
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ing effect on the antigen or influence their internalization; fur-
thermore, the FRET efficiency of dyes coupled to anti-APP
antibodies was too low for the reliable quantification of its oli-
gomerization behavior, probably because of the large inter-an-
tibody distances involved (60). Therefore, we decided to use a
recently described site-directed biolabeling approach that
selectively and covalently labels cell-surface proteins carrying
an ACP domain (61, 62). Using this system, it was indeed pos-
sible to selectively measure the signal of cell-surface APP-ACP
even in the presence of much larger quantities of unlabeled
intracellularAPP-ACP (Fig. 2,A–D). The lifetime of specifically
labeled APP-ACP was derived from the apparent lifetime by
regression analysis of the fluorescence intensity (Fig. 2K; see the
“Experimental Procedures” for details on the regression). This
procedure eliminated the very low, but a non-negligible contri-
bution of unboundor non-specifically boundCoA-488 andper-
mitted the use of all plasma membrane pixels, even those at
extremely low APP concentrations. Co-labeling of membrane-
FIGURE 1. Investigation of APP dimerization using APP-mGFP. A, confocal image of a B103 cell expressing APP-mGFP. B–G, wide-field images of B103 cells
expressing APP-mGFP alone (B–D) or in combinationwith APP-mCherry (E–G). B and E, mGFP channel. C and F, mCherry channel.D andG, mGFP lifetime. Scale
bars: 10m.H, histogramsof FRETefficiencies indifferent experimental conditions.Histograms (thin lines)were fitted toGaussian curves (thick lines). APPdonor
only, 36 cells; APP FRET, 48 cells; K624C-APP donor only, 27 cells; K624C-APP FRET, 21 cells. PDF, probability density function.
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exposed APP-ACPwith amixture of CoA-488 donor and CoA-
547 acceptor dyes establishes the FRET couple for the detection
of APP dimers. An advantage of this technique is that the dye-
labeled FRET partners can be “clamped” to a known and invari-
ant stoichiometry, improving the comparability between differ-
ent conditions.
The lifetime distribution, thus, derived from CoA-488-la-
beled APP-ACP in the absence of acceptor was homogeneous,
with a mean value of 3.31  0.02 ns (Fig. 2, E–G), but it was
reduced considerably in the presence of the FRET acceptor
CoA-547-labeled APP-ACP (Fig. 2,
H–J); the mean value of 2.97 0.02
ns corresponds to a FRET efficiency
of 10.2  0.6%. The covalent dimer
K624C mutant of APP-ACP labeled
with CoA-488 and CoA-547 exhib-
ited a mean FRET efficiency of
11.2  0.5%. Therefore, even wild-
type APP is almost completely
dimerized in the plasma membrane
(Figs. 2L and 3).
The insertion by theACP labeling
method of conformationally uncon-
strained fluorophores between the
two described dimerization inter-
faces in the extracellular domain of
APP (32, 63, 64) makes it very
unlikely that the FRET coupling in
the APP dimer is sensitive to the
K624C mutation in the transmem-
brane domain of APP. Furthermore,
the good fit of the data to our two-
species model (specifically CoA-
488-labeled APP-ACP undergoing
FRET and nonspecific CoA-488
background) over a scale of more
than an order of magnitude of con-
centration (Fig. 2K) showed that
there was no appreciable relation-
ship between the concentration of
labeled APP and FRET efficiency. If
APP monomers frequently under-
went stochastic encounters in the
plasmamembrane or if they formed
higher order aggregates in addition
to dimers, lifetime should reduce
more at higher APP concentrations
because of the increased formation
of FRET-generating higher order
clusters. The observed stringent lin-
earity over a scale of more than an
order of magnitude of fluorescence
signal, thus, strongly supports the
interpretation that the associated
APP molecules detected by fluores-
cence lifetime imaging microscopy
at the plasmamembrane are dimers.
To directly investigate the pres-
ence of specific and stable APP dimers in the plasma mem-
brane, single molecule experiments were undertaken. After
coupling quantum dots to APP-ACP, APP molecules could be
tracked over several minutes (Fig. 4 and supplementalMovie 1)
because of the high photostability of the quantum dots. Single
molecules were observed because the concentration of quan-
tum dots was low enough for sparse coupling to APP, and
unspecific staining of untransfected cells was not observed. Fig.
4B shows that at room temperature some quantum dots
undergo endocytosis, as judged by the increase in velocity and
FIGURE 2. Investigation of cell surface APP dimers using APP-ACP. A–D, confocal image of a B103 cell
expressing APP-ACP-mGFP and labeled with CoA-biotin and 1 nM quantum dots (QD655). A, mGFP fluores-
cence;B, QD655-labeledAPP fluorescence.C, phase contrast image; untransfected cells are devoidof quantum
dot labeling. D, overlay of images A and B. Note the selective plasma membrane staining by CoA-647-labeled
APP-ACP (red) compared with APP-mGFP (green). E–J, wide-field images of APP-ACP-expressing B103 cells
labeledwithCoA-488 alone (E–G) or in combinationwithCoA-547 (H–J). The focal planewas chosen togive the
strongest signal from the plasma membrane, and therefore, does not include neurites. E and H, CoA-488
channel. F and I, CoA-547 channel. G and J, lifetime of CoA-488-labeled APP-ACP. Scale bars: 10 m. K, regres-
sion analysis of the fluorescence lifetime of CoA-488-labeled APP-ACP-expressing B103 cells. The lifetime of
eachpixelwasmultipliedwith its SNRandplotted against SNR. The slopeof the linear fit gives thebackground-
corrected lifetime (see “Experimental Procedures”). Different experimental conditions were vertically dis-
placed for easier display, and parallels (broken lines) to the APP donor-only fit (red) were drawn to facilitate
comparison between the fits. Black, APP donor-only; orange, APP FRET exposed to sAPP; green, APP FRET; red,
K624C-APP FRET. L, histograms of FRET efficiencies in different experimental conditions. Histograms (thin lines)
were fitted to Gaussian curves (thick lines). APP donor-only, 55 cell; APP FRET, 98 cells; APP FRET sAPP, 35
cells; K624C-APP donor-only, 29 cells; K624C-APP FRET, 50 cells. PDF, probability density function.
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directionality because of active endosomal transport, and oth-
ers that had been endocytosed before the beginning of meas-
urement remained in the interior of the cell (cf. Fig. 4B, inset) for
prolonged periods. However, for further analysis only quantum
dots on the cell surfacewere examined. Because of the sparse cou-
pling, it is not tobe expected that in allAPPdimersbothmolecules
are coupled to quantumdots, but in several cases jointmovement
of quantum dots of different colors does show a stable association
between APP molecules (Fig. 4, B and C). Such association per-
sisted for up to 110 s. Two experimental observations suggest that
the jointly moving cell surface APPmolecules are dimers. First, in
several tracks (e.g. Fig. 4C), each of the two color channels displays
the blinking behavior typical of single quantum dots (65). The
quantumdotswere tracked in all three spatial dimensions, and the
images show maximum projections of all z planes, excluding loss
of focus as explanation for the blinking behavior. Second, the dif-
fusion coefficient calculated for cell surface quantum dot-marked
APPmolecules is 3.8 0.5  1011 cm2/s (n	 17 quantumdots in
3 cells), which iswithin the range observed for other plasmamem-
brane resident protein dimers (66). These results thus provide
independent support for dimers as the prevailing interaction state
of plasmamembrane APP.
Having isolated the signal of cell-surface APP from themuch
higher amounts of intracellular APP, it was now possible to
measure the reasons for the higher degree of dimerization at the
cell surface and to search for modulators of the aggregation
state of cell surface APP. The presence of high concentrations
of heparan sulfate side chains in the cell glycocalyx might be
responsible for facilitating APP dimerization in the plasma
membrane, as heparin has been shown to quantitatively dimer-
ize sAPP (40). Indeed, heparinase treatment of live B103 cells
reduces the proportion of wild-type APP dimers in the plasma
membrane by 44  6% (Fig. 5). Heparinase treatment had no
significant effect on the aggregation state of plasma membrane
K624C-APP dimers (Fig. 5).
When searching for the effects of extracellular ligands on the
aggregation state of APP, sAPP is of particular interest
because it has awell knownneuroprotective effect and has been
suggested to counteract the detrimental neurotoxic effects of
A in Alzheimer disease (14–18). The addition of 1 M sAPP
to wtAPP-ACP-expressing cells decreased the FRET efficiency
to 7.0 0.5%. If this diminished FRET efficiency derives from a
physical separation of a subpopulation of APP with an accom-
panying complete loss of FRET, it corresponds to a30% loss of
dimeric APP by reference to the quantitatively dimerized
K624C-APP-ACP measurements (Figs. 2L and 3). This reduc-
tion is comparable with the reduction achieved by heparinase
treatment (Fig. 5).We cannot exclude the possibility that hepa-
rinase and/or sAPP treatment leads to a conformational
change in the APP dimers (e.g. by disrupting only the extracel-
lular dimer interfaces). In this case the fraction of participat-
ing dimers would be even higher. However, the addition of
1 M sAPP had no significant effect on FRET efficiency in
covalent K624C-APP dimers (Fig. 3), again in agreement
with their resistance against heparinase treatment, and this
together with functional data (see below) suggests that
sAPP indeed completely disrupts wtAPP dimers and not
only changes their conformation.
The effect of exogenous sAPP onAPP dimers raises the ques-
tion of whether an endogenous sAPP-ACP fragment generated
fromAPP-ACPby the actionof secretasesmighthave contributed
to our measurements. We, therefore, quantified sAPP in the
medium conditioned by APP-ACP-transfected B103 cell directly
before the addition of the dyes and found the concentration to be
in the subnanomolar range (supplemental Fig. 1). Because endog-
enous sAPP-ACPwas further reducedby thewashing steps before
ameasurement (see “Experimental Procedures”), it is veryunlikely
that it might have influenced the results.
We note that in vivo concentrations of sAPP in cerebrospi-
nal fluid are also in the low nanomolar range (67). The sAPP-
FIGURE 3. Proportion of dimerized APP in different experimental con-
ditions. Left, total cellular APP (cf. Fig. 1). Right, cell surface APP (cf. Fig. 2).
Black, quantitatively dimerized K624Cmutant of APP, normalized to 100%.
Dark gray, K624C-APP in the presence of sAPP. Light gray, wild-type APP
in the absence of biological ligands. White, wild-type APP in the presence
of sAPP. Error bars indicate the S.E. (left) or the error of fit (right). *, p 

0.05; **, p 
 0.001.
FIGURE4.TrackingofAPPusingquantumdots.A, confocal imageof a B103
cell expressing APP-ACP labeledwith CoA-biotin and a 100 pM concentration
of a mixture of quantum dots emitting at 585 nm (green) and 655 nm (red).
Note the colocalization of both quantum dots at several spots. The z plane is
through the middle of the cell. B, time tracks of the quantum dots shown in
panel A, projected into the xy plane (duration190 s). Inset, APPmarkedwith
quantumdots in a lower focal plane (z	 0m, t	 0 s) delineates the contour
of the cell. Cell surface APP monomers and dimers display random walks. *,
APP dimer undergoing endocytosis after 28 s; note the transition from ran-
dom movement to fast directional transport. Ellipse, internalized quantum
dots. Scale bar, 1m. C, APP dimer shown in thewhite square in panels A and
B at higher magnification (1.2-m side length) at different time points.
Images aremaximumprojections into the xyplane. Blinking of 655-nmquan-
tum dot (t	 2.2 s and 30.4 s) and 585-nm quantum dot (t	 17.4s) indicates
that these are single quantum dots.
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inducedmodulation of APP dimerization and signaling, requir-
ing higher concentrations, is thus expected to remain restricted
to spatially confined compartments surrounding axons and
synapses, where sAPP is generated (68).
A possible functional role for APP dissociation in response to
sAPP binding was tested bymeasuring the survival of neuron-
derived cells expressingAPPundermetabolic stress, both in the
absence and in the presence of sAPP. Changes in the meta-
bolic state of the brain, especially a lower availability of intra-
cellular glucose, accompany aging and have been suggested to
contribute to the genesis of sporadic Alzheimer disease (69).
When the B103 neuroblastoma cell line, which contains no
endogenous APP or APP-like proteins (44), was grown for 2
days in the absence of nutrients and serum, cell survival was
low; the number ofmock-transfected cells surviving after 2 days
under metabolic stress was20% that of the number of mock-
transfected cells surviving after 2 days in complete medium.
The addition of sAPP did not significantly change the number
of surviving mock-transfected cells (Fig. 6). However, when
wild-type APP-transfected cells were exposed to sAPP, cell
survival was more than twice as high as in mock-transfected
cells (Fig. 6). Importantly, this effect was specific for wild-type
APP, as the presence of sAPP did
not have a significant effect on the
survival of cells transfected with the
covalent dimer mutant of APP (Fig.
6). Together, these results show that
for sAPP to have a neuroprotective
function, it must be able to dissoci-
ate transmembrane APP dimers in
the plasma membrane. This rein-
forces the hypothesis that the
reduction in FRET efficiencies
indeed corresponds to a complete
disruption of wtAPP dimers. Fur-
thermore, the negligible differ-
ence in survival rates between
mock-transfected and wtAPP-
transfected B103 cells in the
absence of exogenous sAPP cor-
roborates that only very low con-
centrations of neuroprotective
endogenous sAPP fragment are
generated in our model system.
DISCUSSION
Since its discovery over 20 years
ago (7), APP has posed many chal-
lenges for its investigation both with
regard to its role inAlzheimer disease
and during normal development and
neuronal plasticity. One of the more
difficult questionshas been the role of
intact, full-length APP in these pro-
cesses.Althougha largeproportionof
APP is cleaved in various cell com-
partments (55) and the fragments are
secreted or degraded, a small propor-
tionof transmembraneAPPremains stably localized to theplasma
membrane (70). Different lines of evidence have suggested both
growth-promoting and toxic roles for transmembrane APP (19,
20, 22–24, 71), whereas there is unequivocal evidence for a neuro-
protective role of sAPP (14–18). Both inappropriate signaling by
transmembrane APP and a lowered sAPP concentration may,
therefore, contribute to neurodegeneration.
Our detection of APP dimerization by FRET/fluorescence
lifetime imaging microscopy and single-molecule tracking
using site-directed bioconjugation of surface-exposed APP, the
invariant concentration ratio of donor and acceptor labels
inherent to the labeling method, the independence of FRET in
our assay on expression level and label density more than one
order ofmagnitude, and the comparisonwith the constitutively
dimerized K624C-APPmutant control condition permitted for
the first time the rigorous statistical analysis of the monomer/
dimer relationship of plasmamembraneAPP. Themost impor-
tant novelty in our approach is the successful separation of cell
surface APP from the much greater pool of intracellular APP.
We establish an almost complete dimerization of cell surface
APP, apparently involving the presence of heparan sulfate on
the cell surface, and its partial monomerization upon binding of
FIGURE 5. Removal of heparin reduces APP dimerization. A–H, wide-field images of APP-ACP-expressing
B103 cells labeledwith CoA-488 andCoA-547. The focal planewas chosen to give the strongest signal from the
plasma membrane and, therefore, does not include neurites. A, C, E, and G, CoA-488 intensity channel. B, D, F,
and H, lifetime of CoA-488-labeled APP-ACP. A and B, wild-type APP-ACP in control condition. C and D, wild-
type APP-ACP after heparinase treatment. E and F, K624C-APP-ACP in control condition. G and H, K624C-APP
after heparinase treatment. Scale bars: 10m. I, proportion of dimerized APP. Left, K624Cmutant of APP-ACP;
right, wild-type APP-ACP. Black, control condition; white, after incubation with heparinase. Error bars indicate
the S.E. (*, p	 0.011, n	 10–20 cells per condition).
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sAPP. We further show that the sAPP-mediated disruption of
transmembrane APP dimers is required for the neuroprotective
effects of sAPP tooccur.The inability of sAPP to exert the same
protective effect in cells expressing the irreversibly dimerized
K624C-APP mutant points to an underlying mechanism that
depends on themonomerization of APP in themembrane.
Because sAPP can dimerize in solution (32, 40) and is
almost completely equivalent to the extracellular domain of
APP, the dependence of sAPP effects on the dissociation of
transmembraneAPP dimers ismost easily explained by a direct
interactionmodel (Fig. 7). In this model the dimerization inter-
face of the heterodimer sAPP/transmembrane APP would
replace the dimerization interface between transmembrane
APP molecules. Whether interactions of Nogo-66, TAG1, and
integrin 1 with APP and/or sAPP also affect APP dimeriza-
tion (26, 72, 73) remains to be investigated.
In our studieswe did not differentiate between theAPPmod-
ulatory effect of sAPP and sAPPmainly because of a lack of
means of producing sAPP in a eukaryotic system. Given the
importance of secretase switching under stress and pathologi-
cal conditions, this represents an interesting aspect. However,
the action of sAPP to dimerize with transmembrane APP most
likely does not depend on the C-terminal 16 amino acids that
are exclusively present in sAPP and absent in sAPP, as both
the dimerization interfaces known from atomic resolution
studies (32, 63, 64) are present in both secreted APP forms.
Furthermore, the proportion of APP cleaved by -secretase is
much higher than that cleaved by -secretase in brain and can
further increase severalfold (17) to thedetrimentof themajor frac-
tion of APP degraded intracellularly (74), Therefore, under condi-
tions favorable for -secretase cleavage (75), not only the ratio
sAPP/sAPP but also the total amount of sAPP is increased and
may influence APP dimerization in the plasmamembrane.
As it had not been shown before that cell surface APP is
already almost entirely predimerized, the known neurotoxic
effect of certain antibodies (19–22, 24) could have been
assumed to be exerted through the dimerization of cell surface
APP. Rather, our novel data suggest that these antibodies act by
retaining increased amounts of APP dimers at the cell surface
and/or by inducing higher order APP aggregates. This hypoth-
esis is supported by our observation that the fluorescence
intensity of cell surface APP is consistently higher in cells
treated with the antibody 22C11 (data not shown). It is possible
that sAPP, on the other hand, accelerates APP internalization
by disrupting dimers. Another artificial peptide ligand of APP
has been shown to monomerize smaller APP domains and to
modulate A production but without explicitly demonstrating
an effect on the dimerization status of transmembrane APP
(27). It has been speculated that other natural ligands of APP,
e.g. Cu2, may also induce the monomerization of plasmale-
mmal APP (31). Unfortunately, Cu2 quenches the fluores-
cence of CoA-488-labeled APP (data not shown), which pre-
cluded the investigation of its effects by our fluorescence-based
methods. Such dimer-disrupting agents might be beneficial in
that they could decrease both transmembrane APP signaling
and the production of A (27, 31), and our experimental model
is compatible with a systematic screen for such agents.
In conclusion, our results help to clarify the discussion on
toxic versus protective roles of APP by the recognition of differ-
ent pools of transmembrane APP in living cells and indicate a
critical role of the concentration of cell surface APP dimers for
cell behavior. Furthermore, they predict a beneficial effect of
treatments that would decrease cell surface APP dimer concen-
trations and reinforce the importance of increasing sAPP pro-
duction as a treatment option for Alzheimer disease symptoms.
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FIGURE 6. Effect of sAPP on survival of neuroblastoma cells. Cells trans-
fectedwith control plasmid (left), wild-typeAPP (middle), or K624C-APP (right)
and a fluorescent marker plasmid were starved of nutrients and serum for
48 h in the absence (open bars) or the presence of sAPP (solid bars). Cell
numbers are normalized to control cells in the absence of sAPP. S.E. are
indicated. **, p
 0.05; ***, p
 0.001 (n	 20 fields of view, 9 wells).
FIGURE 7. Hypothetical model of sAPP action. Left, in the basal state APP
mainly exists as dimers in the plasma membrane, which may activate cell
death pathways. Part of transmembrane APP is cleaved by -secretase, liber-
ating sAPP into the extracellular space. Right, when sAPP binds to trans-
membrane APP, the dimers are disrupted, leading to increased cell survival.
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